Skip to main content

Neutra Corp

corporate_fare Company Profile

Neutra Corp

NTRR·OTC·Life Sciences·CIK 0001512886

Neutra Corp is a nutraceutical company incorporated in Nevada on January 11, 2011, and reincorporated in Wyoming on August 16, 2019. It markets and participates in the nutraceutical space by bringing products derived from all natural and organic origins, and plans to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is described as an alternative system focusing on natural remedies and the body's vital ability to heal and maintain itself. One nutraceutical sub-market the company intends to participate in is the medical cannabis market. Neutra Corp intends to entrust manufacturing to a nutraceutical contractor to private label all of its products and sell them under its unique brand. Its fiscal year end is January 31. The company states it is constantly combing the industry for the latest technologies and products to test, prove and bring to market, from lighting to dosage devices, from pesticide replacements to plant enhancers. On January 23, 2018, Neutra Corp entered into an agreement with Artillery Labs to sell and market natural nutraceuticals online, with the objective of having its own line of all natural and legal CBD products for sale through Artillery Labs' online sales infrastructure; Artillery Labs will be paid $25,000 upon the successful marketing launch of a product. On August 30, 2019, Neutra Corp purchased all of the outstanding stock of Vivis Corporation, a Wyoming corporation, from Sydney Jim, its CEO, for $35,000 cash and a royalty of 40 percent of gross revenue until $100,000 is paid, declining to 25 percent until an additional $100,000 has been paid, with a 10 percent royalty in perpetuity.

Neutra Corp (OTC:NTRR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for NTRR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-29, rated 7/10.

Recent high-impact activity:

  • Neutra Life Sciences Forms Women's Health JV, Secures New Clinical Trials

Short Interest & Short Volume

On November 17, 2026, 100.0% of NTRR volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)100.0% of 489,250 shares on November 17, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.0001 -50.00% today
52-week range · as of 2026-06-29 $0.000001 – $0.0003
Market cap
$291.79K
Volume
15K (0.0× avg)
3-mo avg 9.1M
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NTRR - Latest Insights

NTRR
Jun 29, 2026, 3:29 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.0001
Real-time Price: $0.0001 info
Change: $0 (0%) info
Market Cap: $291.79K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets